Key takeaways
Remicade (infliximab) and Simponi (golimumab) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Remicade is given through an IV infusion by a healthcare provider, while Simponi can be administered either as a subcutaneous injection. It is also available as an IV infusion under the brand name Simponi Aria. Remicade is available only as a brand medication, whereas Simponi is also only available as a brand medication, making both potentially expensive. Remicade is also available as a brand name medication, but is has several biosimilars available, potentially making it more affordable. Remicade is typically given every 6 to 8 weeks, whereas Simponi is usually injected once a month. Additionally, Remicade can be used in children 6 years and older for certain conditions, while Simponi is available in prefilled syringe and autoinjector forms which are only approved for use in adults. The IV infusion dosage form of Simponi can be used in children. Both medications raise the risk of serious infections and have similar side effects, including causing lupus-like syndrome.
